首页> 外文期刊>Journal of Veterinary Internal Medicine >Consensus Guidelines for Immunosuppressive Treatment of Dogs with Glomerular Disease Absent a Pathologic Diagnosis
【24h】

Consensus Guidelines for Immunosuppressive Treatment of Dogs with Glomerular Disease Absent a Pathologic Diagnosis

机译:缺乏病理诊断的肾小球疾病犬的免疫抑制治疗共识指南

获取原文
获取原文并翻译 | 示例
       

摘要

BackgroundIn certain situations, veterinarians must decide whether or not to recommend immunosuppressive therapy for dogs with suspect glomerular disease in the absence of renal biopsy-derived evidence that active immune mechanisms are contributing to glomerular injury. The purpose of this report is to provide guidelines for the use of immunosuppressive drugs under these conditions. AnimalsAnimals were not used in this study. MethodsRecommendations were developed by a formal consensus method. ResultsFour recommendations were developed and accepted at a high level of consensus (median 92.5% agreement). Renal biopsy should not be performed when contraindications are present or when results will not alter treatment or outcome. Immunosuppressive drugs should not be given when the source of proteinuria is unknown, they are otherwise contraindicated, or a familial nephropathy or amyloidosis is likely. However, they should be considered when dogs are already being given standard therapy and the serum creatinine is >3.0mg/dL, azotemia is progressive, or hypoalbuminemia is severe. Thorough client communication regarding pros and cons of such treatment as well as close and careful patient monitoring is required. Conclusion and Clinical ImportanceThese recommendations can help guide the decision about renal biopsy in patients with proteinuria as well as the use of immunosuppressive drugs in those patients where the decision was made not to perform renal biopsy.
机译:背景技术在某些情况下,如果没有肾活检的证据表明主动免疫机制是导致肾小球损伤的证据,兽医必须决定是否建议对患有肾小球疾病的狗进行免疫抑制治疗。本报告的目的是提供在这些情况下使用免疫抑制药物的指南。动物这项研究未使用动物。方法推荐采用正式的共识方法。结果在高度共识(中位数为92.5%)下,制定并接受了四项建议。存在禁忌症或结果不会改变治疗或结果时,不应进行肾脏活检。当蛋白尿的来源未知,禁忌使用或有家族性肾病或淀粉样变性的可能时,不应给予免疫抑制药物。但是,当犬已经接受标准疗法并且血清肌酐> 3.0mg / dL,氮质血症进展性或低白蛋白血症严重时,应考虑使用它们。客户需要就此类治疗的利弊进行透彻的沟通,并密切密切地监视患者。结论和临床重要性这些建议可帮助指导对蛋白尿患者进行肾脏活检的决策,以及对那些决定不进行肾脏活检的患者使用免疫抑制药物的指导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号